// App-Quantinova.ai

414.0 : Folfirinox (FFX) versus gemcitabine with nab‐paclitaxel (GNP) in the first line treatment (1LTx) of metastatic pancreatic cancer (mPC): A tertiary center experience.

Researchers

Presenter

  • Ivan Barrera

Principal Investigators

  • Sabina Hamalova

  • Jill Ranger

  • Henry Rho

  • Aline Mamo

  • Gerald Batist

  • Petr Kavan

Medical Centers

  • Jewish General Hospital/ McGill Univeristy, Montreal, QC, Canada

  • Montreal University, Montreal, QC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Gemcitabine

  • Paclitaxel

  • FOLFIRINOX

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved